Researchers pinpoint why lymphoma patients may become resistant to specific therapy
Loss of the BCL-2 amplicon and transcriptional reprogramming contribute to resistance to the drug Venetoclax® for those with B-cell lymphomas TAMPA, Fla. and BOSTON -...






